Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell-based therapies today announced the appointment of Philippe Dechamps as General Counsel and Company Secretary, as well as new Executive Management Team member, effective as from 1st of September 2016.

Philippe started his career at the Brussels Bar with De Bandt (now Linklaters) in 1994. He joined the legal team of Solvay in 1998 where he was mostly active in mergers and acquisitions. He then developed and managed the distribution contracts of the cardiovascular businesses of Guidant and Abbott in Europe, Middle East and Africa for more than 5 years, before leaving the pharma and medical device industry to join Delhaize Group in 2008, where he became General Counsel & Company Secretary in March 2015. In this role Philippe was part of the senior leadership team that successfully negotiated and finalized the merger of Delhaize Group and Royal Ahold in July 2016. Philippe holds a Master of Laws from the Harvard Law School, a Master of European Laws from the Vrije Universiteit Brussel and a Master of Laws from the Université Catholique de Louvain.

Dr. Christian Homsy, CEO of Celyad: “We are pleased to welcome Philippe to our executive management team, where he brings over 20 years of expertise in Corporate Affairs. We will greatly benefit from Philippe’s extensive experience in negotiating contracts in the pharma industry.”

Philippe Dechamps, General Counsel & Company Secretary of Celyad: “I am excited to join Celyad and its exceptional team of talents. I have the greatest respect for what has been accomplished by the company to date, and I am impatient to join the leadership team to contribute to its success in the coming years.”

Philippe will be based in Mont-Saint-Guibert, Belgium and will report to Christian Homsy, Chief Executive Officer. 

Download press release(s)

Press release

135.36 Ko

Celyad completes the NKR-2 Phase I trial with successful safety follow-up of the fourth do...

Next News

Celyad completes the NKR-2 Phase I trial with successful safety follow-up of the fourth do...